Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, updates us on long-term results of a Phase Ib study investigating ibrutinib with umbralisib, a PI3Kdelta inhibitor, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
